We have demonstrated delivery of a wide range of materials including small molecules, peptides, proteins and nucleic acids across the stratum corneum following topical administration with minimal impact on barrier functions and viability. This unprecedented flexibility in the choice of cations and anions enables us to engineer diverse ILs with tailor‐made properties for multiple therapeutic areas.
Additionally, the inherent properties of such deep eutectic ILs as broad-spectrum antimicrobial agents in addition to exceptional solvation and permeation enhancement offer phenomenal opportunities in drug discovery and pharmaceutical space.
An ionic liquid (IL) is a salt in which the ions are poorly coordinated, which results in these solvents being liquid below 100°C, or even at room temperature (room temperature ionic liquids, RTIL's).
Our team has accumulated a vast amount of in vitro and in vivo evidence supporting the role of ILs in improving tissue-specific delivery of therapeutic entities into the skin.
The platform we are developing can be used across multiple modalities and diseases, making them a valuable therapeutic platform.
CAGE Bio, TAGCyx, and PeptiStar Announce Execution of a License Agreement for Development and Commercialization of TAGX-0003 for the Treatment of Immunodermatology Diseases Mediated by the IFN-Gamma Pathway